Pharming Group Reports Strong 2025 Financial Turnaround and Key Product Milestones

summarizeSummary

Pharming Group N.V. reported a return to net profitability in 2025 with strong revenue growth for RUCONEST® and Joenja®, alongside significant pipeline advancements and successful remediation of internal control weaknesses.

check_boxKey Events

• Strong Financial Performance in 2025

  The company achieved a net profit of $2.5 million in 2025, a significant improvement from a net loss of $11.8 million in 2024. Revenues increased by 26.6% to $376.1 million, driven by RUCONEST® sales of $317.9 million (+26%) and Joenja® sales of $58.2 million (+29%). Operating profit reached $25.8 million, reversing an $8.6 million operating loss in the prior year, and net cash flows from operating activities turned positive at $54.7 million.

• Joenja® Global Regulatory Progress and US Pediatric Setback

  Joenja® (leniolisib) received marketing authorization in Japan for adult and pediatric patients aged 4 years and older in March 2026, marking its first global approval for children aged 4 to 11. The European Medicines Agency's CHMP also adopted a positive opinion for marketing authorization in the EU. However, the FDA issued a Complete Response Letter in January 2026 for the pediatric sNDA (4-11 years) in the US, requesting additional pharmacokinetic data and clarification on an analytical method.

• Pipeline Strengthened by Acquisition and Clinical Advancement

  Pharming completed the acquisition of Abliva AB in March 2025, adding napazimone (KL1333) for mtDNA-driven primary mitochondrial disease to its late-stage pipeline. The pivotal FALCON study for napazimone passed a futility analysis in 2024, with a readout anticipated in late 2027. Additionally, two Phase II studies evaluating leniolisib for broader primary immunodeficiencies (PIDs) with immune dysregulation are fully enrolled, with top-line data expected in the second half of 2026.

• Remediation of Internal Control Weaknesses

  The company successfully remediated previously disclosed material weaknesses in its internal control over financial reporting as of December 31, 2025, receiving an unqualified opinion from its independent registered public accounting firm.

auto_awesomeAnalysis

Pharming Group N.V.'s 2025 annual report highlights a significant financial turnaround, moving from a net loss in 2024 to a net profit in 2025, driven by robust revenue growth from its key products, RUCONEST® and Joenja®. The company also demonstrated strong operational cash flow generation. Strategically, Pharming advanced its pipeline through the acquisition of Abliva AB and its lead asset napazimone (KL1333), and progressed leniolisib into broader immune dysregulation disorders. While the FDA issued a Complete Response Letter for pediatric Joenja® (4-11 years) in the US, the company is actively addressing the feedback. The successful remediation of previously disclosed material weaknesses in internal control over financial reporting is a notable positive for corporate governance and investor confidence. Overall, the report indicates solid execution of its rare disease strategy and a strengthened financial position.